Tag Archive for: NEPC
Memantine Shows Promise Against Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 2 trial: Tarlatamab for Neuroendocrine Prostate Cancer (NEPC)
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1 Trial of 225Ac-ETN029 for Neuroendocrine Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Trial: MT-4561 Targeting BRD4 in Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNEPC
Phase 2 Trial: ZG006 a New Immunotherapy for Neuroendocrine Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPreclinical: Targeting NSD2, a Promising Strategy Against Treatment-Induced Neuroendocrine Prostate Cancer
/0 Comments/in Preclinical Research/by MaxNew Hope for Neuroendocrine Prostate Cancer: Targeting Mitochondrial HSP60
/0 Comments/in Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Phase 1 Trial: 161Tb-PSMA Offers Hope After Lutetium Failure in mCRPC October 6, 2025
- Newsletter 40/2025 October 5, 2025
- Optimized Epigenetic Regulators for Durable Gene Silencing (PCSK9) October 4, 2025
- Efficacy and Safety of Combination ARSI, Denosumab, and Local Radiotherapy in Poly-Metastatic Prostate Cancer October 4, 2025